作者
Gabriella Macchia,Maura Campitelli,Donato Pezzulla,Simona Lucci,A. Fodor,D. Russo,Vittoria Balcet,Paolo Bonome,Stefano Durante,Lorena Draghini,Francesca Titone,Giuseppe Roberto D’Agostino,Marinella Tamburo,Martina Ferioli,Edy Ippolito,F. Tortoreto,L. Caravatta,Francesca De Felice,Aida Di Stefano,Mara Fanelli,Savino Cilla,Francesco Cosentino,Cláudia Marchetti,Vanda Salutari,Serena Maria Boccia,A.G. Morganti,Maria Antonietta Gambacorta,Anna Fagotti,Sandro Pignata,Giovanni Scambia,Gabriella Ferrandina,Francesco Deodato
摘要
MITO-RT3/RAD (NCT04593381) is a prospective multicenter Phase II trial designed to assess the effectiveness and safety of stereotactic body radiotherapy (SBRT) in patients diagnosed with oligometastatic ovarian cancer (oligo-MPR-OC). In this report, we provide the results of the trial in the setting of lymph node disease.
杳鸢
彭于彦祖
yar
pcr163
HEIKU
寻道图强
Ganlou
爱静静
咻咻
模糊中正
iNk
带头大哥
Liou
萧水白
Leonardi
平常的毛豆
shinysparrow
坚强的广山
cannon8
tuanheqi
皖公网安备34019202002308
